|
Allele Symbol Allele Name Allele ID |
Gt(ROSA)26Sortm2(cre/ERT2)Brn targeted mutation 2, Anton Berns MGI:3764519 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
23 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
|
|
• in the bone marrow of tamoxifen-treated mice
|
|
• few early T cell progenitors in the thymus of tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• reduced 7-fold in tamoxifen-treated mice
|
|
• in the bone marrow of tamoxifen-treated mice
• however, the number of B cells in the spleen, lymph node and peripheral blood is normal
|
|
• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice
|
|
• in the bone marrow of tamoxifen-treated mice
|
|
• reduced LSK and lymphoid-primed multipotent progenitors in tamoxifen-treated mice
|
|
• tamoxifen-treated LSK cells exhibit a complete loss of lymphoid development
|
|
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
|
|
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
|
|
• complete loss of lymphoid development in tamoxifen-treated bone marrow cells is cell autonomous
|
|
• in the bone marrow of tamoxifen-treated mice
|
|
• few early T cell progenitors in the thymus of tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in the bone marrow of tamoxifen-treated mice
• however, the number of B cells in the spleen, lymph node and peripheral blood is normal
|
|
• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice
|
|
• in the bone marrow of tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• early B cell development is rescued in tamoxifen treated mice
|
|
• reduced LSK and lymphoid-primed multipotent progenitors in tamoxifen-treated mice
|
|
• tamoxifen-treated LSK cells exhibit a complete loss of lymphoid development
|
| N |
• early B cell development is rescued in tamoxifen treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice
• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time
• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining
|
|
• after 200 days of tamoxifen treatment tumors are smaller than fully developed basal cell carcinomas and exhibit decreased proliferation indicating regression
|
|
• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice
• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time
• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| basal cell carcinoma | DOID:2513 | J:158915 | ||
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice
• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice
|
|
• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 326 days
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice
• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice
|
|
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
|
|
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
|
|
• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented
• however, the DN4 population is stable after tamoxifen treatment
|
|
• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, circulating B220high, IgD+ B cells are increased compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1tm1Jwnd control mice)
|
|
• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, bone marrow B220low pre-B cells are lower than in Ptch1tm1Jwnd control mice
|
|
• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
• however, granulocyte-macrophage lineage specification is normal following treatment with tamoxifen
• following treatment with tamoxifen, the Lin-c-kithighSca-1high population is increased while the population of Lin-c-kitlowSca-1low are underrepresented compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
|
|
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
|
|
• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented
• however, the DN4 population is stable after tamoxifen treatment
|
|
• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, circulating B220high, IgD+ B cells are increased compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1tm1Jwnd control mice)
|
|
• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, bone marrow B220low pre-B cells are lower than in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
|
|
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks is 376 days compared with 441 days for control mice
|
|
• hamartomatous gastrointestinal cystic tumors in 4 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
• in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• restoration of normal thymus if cre induction with tamoxiphen occurs before 4 months of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at E15.5 following tamoxifen treatment at E10.5
|
|
• at E15.5 following tamoxifen treatment at E10.5
|
|
• at E15.5 following tamoxifen treatment at E10.5
|
|
• at E15.5 following tamoxifen treatment at E10.5
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• tamoxifen-treated mice exhibit rescued total bone marrow and LSK cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Severe hypocellularity in Nle1tm1Cba/Nle1tm1.1Cota Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ bone marrow, with capillaries saturated with erythrocytes
|
• mice die 10 to 13 days after tamoxifen treatment
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• defects in secondary lymphoid organs in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• 7 to 9 days after tamoxifen treatment
|
|
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice
|
| N |
• hematopoietic stem cell mobilization occurs normally in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• tamoxifen-treated mice exhibit cell autonomous defects in hematopoiesis
|
|
• in tamoxifen-treated mice
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice
|
|
• in tamoxifen-treated mice
|
|
• severe in tamoxifen-treated mice
|
|
• decreased in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• reduced hematopoietic stem cell and multipotent progenitor quiescence in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in tamoxifen-treated fibroblasts
|
|
• proliferation of mouse embryonic fibroblasts is arrested 24 hours after tamoxifen-treatment unlike in control cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen-treated mouse embryonic fibroblasts exhibit a 2-fold reduction in S-phase cells and an increase in G1 phase cell compared with control cells
|
|
• tamoxifen-treated mouse embryonic fibroblasts exhibit growth arrest compared with control cells
|
|
• in tamoxifen-treated mouse embryonic fibroblasts
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• no increase in heart weight, no dilation, and no fibrosis when tamoxifen is used to induce loss of expression in neonatal mice unlike when expression is absent in embryonic stages
|
|
• in cultured cardiomyocytes after tamoxifen induction 22% become binucleated while very few cells were binucleate before tamoxifen exposure
|
|
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission
|
|
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission
|
|
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission
|
|
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• cultured tamoxifen-treated DN1, DN2, and DN3 thymocytes differentiate into natural killer-like cells and kill stromal feeder cells unlike similarly treated wild-type thymocytes
• cultured spleen and thymus cells treated with tamoxifen exhibit differentiation into induced T to natural killer cells (ITNK) unlike cells from similarly treated wild-type cells
• tamoxifen-treated thymocytes transplanted into Rag2 Il2rg null mice exhibit an increase in ITNK cells compared with mice transplanted with similarly treated wild-type mice
|
|
• reprogrammed induced T to natural killer cells (ITNK) transplanted into Rag2 Il2rg null suppress metastasis of transplanted B16F10 melanoma cells
|
|
• cultured tamoxifen-treated DN1, DN2, and DN3 thymocytes differentiate into natural killer-like cells and kill stromal feeder cells unlike similarly treated wild-type thymocytes
• cultured spleen and thymus cells treated with tamoxifen exhibit differentiation into induced T to natural killer cells (ITNK) unlike cells from similarly treated wild-type cells
• tamoxifen-treated thymocytes transplanted into Rag2 Il2rg null mice exhibit an increase in ITNK cells compared with mice transplanted with similarly treated wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries
|
|
• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice
|
|
• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries
|
|
• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in un-induced mice
• however, tamoxifen induction rescues thymus size
|
|
• Vgamma4+ gamma delta T cells in the peripheral lymph nodes, spleen, lung and liver despite tamoxifen treatment of adult mice
|
|
• absent IL17+ cells despite tamoxifen treatment of adult mice
|
|
• Vgamma1+ gamma delta T cells in the spleen, lung and liver despite tamoxifen treatment of adult mice
|
|
• in un-induced mice
• however, tamoxifen induction rescues thymus size
|
|
• Vgamma4+ gamma delta T cells in the peripheral lymph nodes, spleen, lung and liver despite tamoxifen treatment of adult mice
|
|
• absent IL17+ cells despite tamoxifen treatment of adult mice
|
|
• Vgamma1+ gamma delta T cells in the spleen, lung and liver despite tamoxifen treatment of adult mice
|
|
• in un-induced mice
• however, tamoxifen induction rescues thymus size
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
|
|
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas
|
|
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas
|
|
• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands
• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles
|
|
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
|
|
• lung tumors of tamoxifen treated mice are adenocarcinomas
|
|
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
|
|
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas
|
|
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas
|
|
• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands
• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles
|
|
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
|
|
• lung tumors of tamoxifen treated mice are adenocarcinomas
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen treated mice exhibit shortened lifespan
|
|
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics
|
|
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics
|
|
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics
|
|
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following exposure to silica, the lung tissue of these mice exhibits significantly less inflammatory cell infiltration than that of wild-type mice.
|
|
• following exposure to silica, the lung tissue of these mice exhibits significantly less inflammatory cell infiltration than that of wild-type mice.
|
|
• at 6 months of age, these mice may exhibit some alveolar space enlargement
|
|
• at 6 months of age, these mice exhibit mild septal thickening
|
|
• the lungs of these mice exhibit no histologically apparent alterations in fibrosis following exposure to silica
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• upon induction with 4-hydroxytamoxifen (4-OHTA), 2/4 mice develop regional keratoacanthomas at site of drug application within 8 weeks
|
|
• 2/4 induced animals acquire lymphoma
|
|
• 2/4 induced animals acquire lung tumors
|
|
• upon induction with 4-hydroxytamoxifen (4-OHTA), 2/4 mice develop regional keratoacanthomas at site of drug application within 8 weeks
|
|
• 2/4 induced animals acquire lung tumors
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/16/2024 MGI 6.23 |
|
|
|
||
Analysis Tools